# C_2007067EN.01001501.xml

| 23.3.2007 | EN | Official Journal of the European Union | C 67/15 |
| --- | --- | --- | --- |

23.3.2007

EN

Official Journal of the European Union

C 67/15

---

Prior notification of a concentration

(Case COMP/M.4569 — GE/Abbott Diagnostics Division

(Text with EEA relevance)

(2007/C 67/06)

| 1. | On 15 March 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking General Electric Company (‘GE’, USA) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of parts of Abbott Laboratories' laboratory and point-of-care in vitro diagnostics division (‘ADD’, USA) by way of purchase of assets. Abbott Laboratories' Molecular Diagnostics and Diabetes Care businesses are not part of the concentration and will remain part of Abbott Laboratories. |
| --- | --- |

1.

On 15 March 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking General Electric Company (‘GE’, USA) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of parts of Abbott Laboratories' laboratory and point-of-care in vitro diagnostics division (‘ADD’, USA) by way of purchase of assets. Abbott Laboratories' Molecular Diagnostics and Diabetes Care businesses are not part of the concentration and will remain part of Abbott Laboratories.

1

in vitro

| 2. | The business activities of the undertakings concerned are:






  — | for GE: a global diversified manufacturing, technology and services company; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for GE: a global diversified manufacturing, technology and services company;

| — | for ADD: supply of in vitro diagnostic systems and products for hospitals, medical laboratories and physicians' offices. |
| --- | --- |

—

for ADD: supply of in vitro diagnostic systems and products for hospitals, medical laboratories and physicians' offices.

in vitro

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4569 — GE/Abbott Diagnostics Division, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Bruxelles/Brussel |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4569 — GE/Abbott Diagnostics Division, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Bruxelles/Brussel

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---